Global Gene Therapy Market Size, Worth and Forecast with CAGR Through 2022

Gene Therapy Market: Gene therapies are generally meant for one time or short duration treatments, they are customized to individuals confined to small patient populations. Therefore, manufacturing firms are expected to seek premium prices for these therapies.

PUNE, INDIA - August 14, 2019 /MarketersMedia/ —

Growing at a CAGR of over x% the global gene therapy market is forecast to hit $363 million by 2022 from $x million in 2017. Strengthened by recent approvals of Kymriah, Yescarta and Luxturna in the US, and a committed European, Japanese and Chinese environment, gene therapy is set to become a significant player in the bio-pharmaceutical industry. The space covers many therapeutic areas specifically, oncology, rare diseases, Parkinson’s, HIV, severe combined immuno-deficiencies (SCID) and hemophilia. Gene Therapy Market is driven by over 2,200 clinical trials globally, with over 55% of this occurring in the US, followed by Europe, Canada and China. Recently, in November 2017, the FDA indicated that gene therapies will now qualify for a fast approval process, which will bring more therapies to market faster. However, the space also has significant challenges, such as manufacturing logistics, reimbursement and its high cost. This 310 page market analysis cutting-edge report tackles this growing but challenging industry, it highlights its strengths, weaknesses and opportunities and provides a comprehensive account of major companies, clinical trials and technological advancement.

Get Free Sample Copy of Gene Therapy Market Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=1370259

Since the FDA approved Kymriah (tisagenlecleucel), Yescarta (Axicabtagene ciloleucel) and Luxturna (voretigene neparvovec-rzyl) in 2017, the US gene therapy space has expanded significantly, underlined by the fact that over 55% of completed and ongoing trials are located in this geographic. Growth in the gene therapy industry has resulted in new commercial initiatives and the emergence of new startups and spin-off biotechs. Furthermore, gene therapy specifically has raised well over $600 million of venture capital in the last five years. Early stage companies have raised seed, Series A and Series B investment steadily since the market took off, including Spark Therapeutics, Avalanche Biotech, uniQure, Voyager Therapeutics, Editas Medicine and GenSight.

This report provides the reader with:

• Current Global Gene Therapy Market Worth and Forecast with CAGR Through 2022
• Sub-Market Worth by Therapeutic Area (Cancer, Rare Diseases, Cardiovascular, Neurological, Ocular) and Forecast with CAGR Through 2022
• Sub-Market Worth by Geography (Americas, Europe, RoW) and Forecast with CAGR Through 2022
• Sub-Market Worth by Technology (Gene Product, Service, Viral Vectors) and Forecast with CAGR Through 2022
• Insight into gene therapy technologies, challenges associated with developing therapeutic genes and disadvantages of gene therapy.
• Full outline of the gene therapy industry from the formative years through to products discovered during 1990 and 2017.
• Detailed descriptions of commercialized products approved between 2003 and 2017 that include: Gendicine, Rexin-G, Oncorine, Neovasculgen, Glybera, Imlygic, Strimvelis, Zalmoxis, Kymriah, Yescarta and Luxturna.
• Description of seven of the Phase III product candidates that include: Generx, Collategene, LentiGlobin, Lenti-D, VM-202, Invosa and GS-010.
• Description of 21 Phase II product candidates that are set to have significant market share.
• Commercialization status of gene therapies in by geographic region
• Evaluation of gene therapy pricing
• Description of the firstever warranty offer by GSK for Strimvelis.
• A detailed analysis of various types of viruses used as vectors.
• Description of clinical applications of gene therapy and the various genetic and infectious diseases addressed by gene therapy.
• Description of 77 companies that are directly and indirectly associated with gene therapy industry.

Get Discount on Global Gene Therapy Market Analysis & Forecast to 2022
https://www.reportsnreports.com/contacts/discount.aspx?name=1370259

Key Questions Answered in this Report:

• What is the size of gene therapy market?
• What is the CAGR and market size over the next five years?
• What are the different sub-markets and their worth/CAGR over the next five years?
• What is gene augmentation therapy?
• What is suicide gene therapy?
• How is ex vivo gene delivery different from in vivo gene delivery?
• What are the types of gene therapies classified on the basis of targeted cell types?
• What is the role of CRISPR technology in gene therapy?
• What are the approved gene therapy products?
• How many gene therapy product candidates have reached the Phase III stage?
• How many Phase II gene therapy product candidates are there?
• What is the commercialization status of gene therapies in E.U. member countries?
• What are the prices of gene therapy products?
• What are the reasons for this extortionate pricing of gene therapies?
• Which company is offering warranty for its gene- therapy product?
• What is the current strength of gene therapy industry?
• Is it true that the real strength of gene therapy industry is based on the number of clinical trials?
• What is the total number of ongoing clinical trials as of 2017?
• What is the distribution of clinical trials by geography?
• Which countries are associated with gene therapy clinical trials?
• What are the major indications addressed by the clinical trials?
• Which genes are transferred in these clinical trials?
• How many Big Pharma are associated with the gene therapy industry?
• What are non-viral and viral vectors?
• What are the various features of viral vectors?
• Which viral vectors are predominantly used in gene therapy clinical trials?
• What are the major diseases addressed by therapeutic genes?
• Where is the gene therapy market heading, and what opportunities and challenges will it face?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1370259

Major Pointers From Table of Contents:
1.0 Introduction
2.0 Gene Therapy: The Basics
3.0 Historic Overview of Gene Therapy
4.0 Gene Therapy Phase III Product Candidates
5.0 Gene Therapy Phase II Product Candidates
6.0 Commercialization, Cost and Warranty of Gene Therapies
7.0 The Strength of Gene Therapy Industry
8.0 Vectors for Gene Delivery
9.0 Clinical Applications of Gene Therapy
10.0 Market Analysis
11.0 Manufacturing of Viral Vectors and Logistics
12.0 Company Profiles

Contact Info:
Name: Ganesh Pardeshi
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1370259-global-gene-therapy-market-analysis-forecast-to-2022.html

Source URL: https://marketersmedia.com/global-gene-therapy-market-size-worth-and-forecast-with-cagr-through-2022/88908116

Source: MarketersMedia

Release ID: 88908116

Latest News

Global shares mostly rise after Wall Street rally on Huawei

Aug 21, 2019

TOKYO — Global shares were mostly higher Tuesday after Wall Street rallied on the U.S. decision to give Chinese telecom giant Huawei another 90 days to buy equipment from American suppliers. That decision appeared to inspire a buying mood among investors eager for any signs of progress in the trade war between the U.S. and China. France's CAC 40 added nearly 0.2% in early trading to 5,380.18, while Germany's DAX inched up nearly 0.1% to 11,723.98. Britain's FTSE 100 rose 0.2% to 7,205.60. U.S. shares were set to drift higher with Dow futures edging up 0.1% to 26,143. S&P 500...

Die-hard Hong Kong protesters defend tactics as unity cracks

Aug 21, 2019

HONG KONG — On a recent sweltering Saturday, a day now reserved for protest in Hong Kong, a demonstrator named Wayne stepped past a row of plastic barricades, lifted a pair of binoculars and squinted. Four hundred meters away, a line of riot police stood with full-length shields, batons and tear-gas launchers. It was a familiar sight for Wayne after more than two months on the front lines of Hong Kong's pro-democracy demonstrations. Face-offs with police have become part of the 33-year-old philosophy professor's new normal. The stories of Wayne and three other self-described "front line" protesters interviewed by The...

With eyes on election, White House insists economy is strong

Aug 21, 2019

WASHINGTON — The "fundamentals" of the U.S. economy are solid, the White House asserted on Monday, invoking an ill-fated political declaration of a decade ago amid mounting concern that a recession could imperil President Donald Trump's reelection. Exhibiting no such concern, senior adviser Kellyanne Conway declared to reporters, "The fact is, the fundamentals of our economy are very strong," It's a phrase with a history. Republican John McCain was accused of being out of touch when he made a similar declaration during the 2008 presidential campaign just hours before investment bank Lehman Brothers filed for bankruptcy, setting off a stock...

Nebraska moves all girls out of facility for troubled youth

Aug 21, 2019

LINCOLN, Neb. — Nebraska officials are moving 24 teenage girls out of a state-run facility for female juvenile offenders after learning that many were confined to buildings with fire hazards, holes in the wall and mold and water damage. The Department of Health and Human Services announced the move Monday after some state lawmakers voiced concerns about the conditions and a lack of staff and programming at the Youth Rehabilitation and Treatment Center in Geneva. The campus in rural, central Nebraska serves as a rehabilitation center for girls ages 14-18 who have broken the law and been rejected by other...

74% of economists in survey see US recession by end of 2021

Aug 21, 2019

WASHINGTON — A strong majority, 74%, of U.S. business economists appear sufficiently concerned about the risks of some of President Donald Trump's economic policies that they expect a recession in the U.S. by the end of 2021. The economists surveyed by the National Association for Business Economics, in a report released Monday, mostly didn't share Trump's optimistic outlook for the economy, though they generally saw recession coming later than they did in a survey taken in February. Thirty-four percent of the economists surveyed said they believe a slowing economy will tip into recession in 2021. That's up from 25% in...

Search
Financial Markets

About Us

Established in 2015, The Upstocker provides insights on financial reports, commentary, and investment data to traders so that you can make better investment decisions.

Contact us: sales[at]theupstocker.com

Subscribe Now!